.
122. Goli RR, Contractor MM, Nathan A, Tuteja S, Kobayashi T, Giri J.
Antiplatelet therapy for secondary prevention of vascular disease
complications. Curr Atheroscler Rep 2017;19:56.

123. Johnson ES, Lanes SF, Wentworth CE 3rd, SatterÔ¨Åeld MH, Abebe BL,
Dicker LW. A metaregression analysis of the dose-response effect of
aspirin on stroke. Arch Intern Med 1999;159:1248-53.
124. Rothwell PM, Algra A, Chen Z, Diener HC, Norrving B, Mehta Z. Effects of aspirin on risk and severity of early recurrent stroke after
transient ischaemic attack and ischaemic stroke: time-course
analysis of randomised trials. Lancet 2016;388:365-75.
125. Alberts MJ, Bergman DL, Molner E, Jovanovic BD, Ushiwata I,
Teruya J. Antiplatelet effect of aspirin in patients with cerebrovascular disease. Stroke 2004;35:175-8.
126. Kasotakis G, Pipinos II, Lynch TG. Current evidence and clinical
implications of aspirin resistance. J Vasc Surg 2009;50:1500-10.
127. A randomized trial of anticoagulants versus aspirin after cerebral
ischemia of presumed arterial origin. The Stroke Prevention in
Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol 1997;42:
857-65.
128. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al.
A comparison of warfarin and aspirin for the prevention of recurrent
ischemic stroke. N Engl J Med 2001;345:1444-51.
129. Halkes PH, van Gijn J, Kappelle LJ, Koudstaal PJ, Algra A. Medium
intensity oral anticoagulants